Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors

Open to people ages 18-100

• The participant must provide study-specific informed consent prior to any study specific procedures and authorization permitting release of personal health information.
• The participant must have a first time diagnosis of non-metastatic breast cancer which is Stage I-III.
• The participant must have a score of less than 12 on the PROMIS Adult v2.0 - Cognitive Function 4a.
• Participants must be at least 6 months and no more than 5 years (after completion of initial surgery +/- adjuvant chemotherapy/radiation therapy) and targeted therapies (e.g., PARP inhibitors, CDK4/6, or immunotherapy). Participants may still be taking endocrine therapy and/or trastuzumab.
• The participant must be able to understand, speak, read, and write in English or Spanish.

• Scoring less than or equal to 3 on the 6-item cognitive screen.
• Patient Health Questionnaire-2 item (PHQ-2) score of greater than or equal to 3.
• Definitive clinical or radiologic evidence of metastatic disease.
• Current or past history of another cancer. Patients with history of only non-melanoma skin cancer or in situ cervical cancer without chemotherapy treatment would be eligible.
• Previous exposure to chemotherapy treatment for another cancer or due to other medical condition (e.g. methotrexate exposure for treatment of rheumatoid arthritis).
• Previous central nervous system (CNS) radiation, intrathecal therapy or CNS-involved surgery.
• Participants with history of stroke, traumatic brain injury, brain surgery, Alzheimer's disease or other dementia.
• Participants with active substance abuse and/or in treatment for substance abuse, or history of bipolar disorder, psychosis, schizophrenia, ADHD, or learning disability.
• Participants who are enrolled in an active behavioral intervention (e.g., occupational therapy, physical therapy, etc.) or pharmaceutical intervention or who are in the follow-up phase of a cancer control trial or therapeutic trial that has extensive PRO follow-up after treatment ends. Participants who are enrolled in a therapeutic trial in which they have completed active treatment and require only minimal follow-up monitoring of toxicity and/or survival analysis (cancer-related mortality or all-cause mortality) would be eligible.
• Hearing impairment unless adequately corrected with hearing aids to be able to hear over the phone for the neuropsychological testing.